Add time:09/06/2019         Source:sciencedirect.com

The pyrrolopyrimidine, SANGIVAMYCIN (cas 18417-89-5), and the adenosine analog, xylosyladenine, were examined for their effects on the synthesis and methylation of polysomal RNA in Ehrlich ascites tumor cells in vitro. The synthesis of non-polyriboadenylic acid (non-poly (A) −) and poly(A)-containing RNA was inhibited 50 per cent at concentrations of 7 × 10−6 M and 3 × 10−6 M xylosyladenine, respectively, when adenosine deaminase was inhibited with 2'-deoxycoformycin. Sangivamycin inhibited the synthesis of non-poly(A)- and poly(A)RNA by 50 per cent at concentrations of 5 × 10−5 M and 2 × 10−5 M respectively. Electrophoretic separation of non-poly(A)RNA into rRNA and tRNA indicated that the inhibitory effects of both drugs were more pronounced on 28S than on 18S rRNA, and that xylosyladenine but not sangivamycin inhibited the synthesis of tRNA. Assessment of the effects of both analogs on the methylation of polysomal RNA revealed that xylosyladenine inhibited the methylation of nonpoly(A)-and poly(A)RNA, while sangivamycin only weakly affected the latter species of RNA. Base methylation of the affected species of RNA was inhibited slightly more than 2'-O-methylation by both drugs. These results indicate that sangivamycin is a more selective inhibitor of polysomal RNA in comparison to xylosyladenine under conditions where adenosine demainase is not a limiting factor.

We also recommend Trading Suppliers and Manufacturers of SANGIVAMYCIN (cas 18417-89-5). Pls Click Website Link as below: cas 18417-89-5 suppliers